Oxygenta Pharmaceutical Reports Strong Sales Growth Amidst Profitability Challenges in June 2025

Aug 14 2025 09:44 PM IST
share
Share Via
Oxygenta Pharmaceutical's financial results for the quarter ending June 2025 reveal strong net sales growth of 178.81% year-on-year, totaling Rs 64.60 crore. However, the company faces challenges with significant declines in profit before tax, profit after tax, and operating profit, alongside a deteriorating operating profit margin.
Oxygenta Pharmaceutical has recently reported its financial results for the quarter ending June 2025, revealing a complex picture of its performance. The company has experienced a notable shift in its evaluation, with its score adjusting to -1 from 13 over the past three months.

On a positive note, Oxygenta's net sales for the latest six months reached Rs 64.60 crore, reflecting a significant year-on-year growth of 178.81%. This indicates a strong sales trend that could be beneficial for the company's market position.

However, the financial results also highlight several challenges. The profit before tax less other income (PBT) for the quarter stands at Rs -8.31 crore, marking a substantial decline year-on-year. Similarly, the profit after tax (PAT) is reported at Rs -6.10 crore, which also shows a significant decrease compared to the previous year. The operating profit has reached its lowest point in five quarters at Rs -6.83 crore, and the operating profit margin has deteriorated to -45.14%. Additionally, earnings per share (EPS) have fallen to Rs -1.65, indicating a decline in profitability.

Overall, Oxygenta Pharmaceutical's recent financial results reflect a mix of strong sales growth alongside significant challenges in profitability and operational efficiency.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News